The FDA has approved Silenor (doxepin tablets, from Somaxon Pharmaceuticals) for the treatment of insomnia characterized by difficulty with sleep maintenance.

Molnlycke Health Care announced the launch of Hibiclens General Skin Cleansing Patient Kit that is to be used at home prior to surgery as part of a strategy to minimize surgical-site infections and hospital-acquired infections.

Quinnova announced the launch of Neosalus Cream, a non-steroidal anti-inflammatory cream for the treatment of various dermatoses (eg, atopic dermatitis, contact dermatitis, and hand eczema).

The FDA has approved a five-day dosing regimen for Dacogen (decitabine for injection, from Eisai) to treat patients with myelodysplastic syndromes (MDS).

The FDA and The Medicines Company have notified healthcare professionals of an additional recall of 4 lots of Cleviprex (clevidipine butyrate injectable emulsion).

The FDA has ordered Glenmark Generics and Konec Inc. to stop marketing unapproved nitroglycerin tablets.

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

The FDA has notified healthcare professionals and patients that at this point, the data that have been reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.